BZL101
Navigation Links
BZL101 in Medical News
Bionovo to Present at Wall Street Analyst Forum's 20th Annual Institutional Investor Conference
...d or currently on the market. bzl101 and other Cancer Drug Candidates ...the powerful and selective mechanism of action for bzl101 in cancer tumors. Another study was presen...8. Results from a second clinical study of bzl101 in advanced breast cancer was presented at ASCO, i...Bionovo Announces Presentation at the National Cancer Institute
...o be leaders in their markets. Bionovo's clinical pipeline of drug candidates includes Menerba (MF101) for the treatment of menopausal hot flashes and bzl101 for the treatment of advanced breast cancer. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the s...Bionovo Announces Cost Control Measures Taken
...o be leaders in their markets. Bionovo's clinical pipeline of drug candidates includes Menerba (MF101) for the treatment of menopausal hot flashes and bzl101 for the treatment of advanced breast cancer. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the s...Bionovo Announces 2007 Financial Results and Highlights
...er Research (AACR). The presentation described how bzl101 elicits its cytotoxic activity on cancer cel... patients into a Phase 1/2 clinical trial of bzl101 for the treatment of advanced breast cancer, after presenting positive Phase 1 findings of bzl101 at the American Association of Cancer Resear...BZL101 in Medical Technology
EMERYVILLE, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Bionovo, Inc.
(Nasdaq: BNVI ) announced the company will present results from the Phase 1B
clinical trial of their lead drug candidate for advanced metastatic breast
cancer, BZL101, at the Society for Integrative Oncology's Fifth Internationa...
EMERYVILLE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) announced today that its drug candidate for metastatic breast cancer, BZL101, will advance to Phase 2 clinical testing after the successful completion of a second Phase 1 clinical trial. The Phase 1B clinical...
- Results Presented at American Society of Clinical Oncology 44TH Annual Meeting - EMERYVILLE, Calif., June 2 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI ) today announced results from a second ongoing clinical trial of BZL101, an oral drug candidate, in...
BZL101 selectively kills cancer cells but not normal cells EMERYVILLE, Calif., April 1 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI ) today announced the publication of a peer-reviewed article in the journal Cancer Biology and Therapy that elucidates the molecular mechanisms un...
... for cancer cell apoptosis (cell death) induced by bzl101 while leaving normal cells unaffected. As explaine...ctor of Cancer Research at Bionovo, the ability of bzl101 to induce apoptosis is due to attenuation of mitoc... of life conditions associated with menopause, and bzl101 is in Phase 1/2 for the treatment of advanced brea...
EMERYVILLE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) announced today that its drug candidate for metastatic breast cancer, BZL101, will advance to Phase 2 clinical testing after the successful completion of a second Phase 1 clinical trial. The Phase 1B clinical...
- Results Presented at American Society of Clinical Oncology 44TH Annual Meeting - EMERYVILLE, Calif., June 2 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI ) today announced results from a second ongoing clinical trial of BZL101, an oral drug candidate, in...
BZL101 selectively kills cancer cells but not normal cells EMERYVILLE, Calif., April 1 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI ) today announced the publication of a peer-reviewed article in the journal Cancer Biology and Therapy that elucidates the molecular mechanisms un...
Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
...es of its innovative breast cancer drug candidate, bzl101 were well tolerated. As a result, the company will... available efficacy information." About BZL101 bzl101 is an oral drug designed for the treatment of adva...argely on glycolysis (>85%) for energy production. bzl101 leads to energy collapse in cancer cells by inhibi...... for cancer cell apoptosis (cell death) induced by bzl101 while leaving normal cells unaffected. As explaine...ctor of Cancer Research at Bionovo, the ability of bzl101 to induce apoptosis is due to attenuation of mitoc... of life conditions associated with menopause, and bzl101 is in Phase 1/2 for the treatment of advanced brea...
Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in Phase 2 Trial
...men's health. The company has two drugs in clinical testing. MF101 has completed Phase 2 for quality of life conditions associated with menopause, and bzl101 is in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in development for breast cancer, pancrea...BZL101 in Biological Technology
Bionovo Announces 2008 Highlights and Year-End Financial Results
...d or currently on the market. bzl101 and other Cancer Drug Candidates ...the powerful and selective mechanism of action for bzl101 in cancer tumors. Another study was presen...8. Results from a second clinical study of bzl101 in advanced breast cancer was presented at ASCO, i...Bionovo Reports Third Quarter 2008 Financial Results
... of advanced breast cancer, menopausal hot flashes, and menopausal vaginal atrophy. Recent advances have included: -- The Phase 1 portion of the bzl101 Phase 1/2 clinical trial for advanced metastatic breast cancer has now been completed successfully, showing positive safety and tolerabil...Bionovo Reports Second Quarter 2008 Financial Results
...rence of $4.6 million. Company Highlights -- The Phase 1 portion of the bzl101 Phase 1/2 clinical trial for advanced metastatic breast cancer continues su...al trials for both MF101 and VG101." "We are very excited at the progress bzl101 is making in the clinical trials for advanced breast cancer. This drug cand...Bionovo Reports First Quarter 2008 Financial Results
...th $33.3 million, a difference of $3.9 million. Company Highlights -- Patient enrollment and dosing continues in the Phase 1 portion of the bzl101 Phase 1/2 clinical trial for advanced metastatic breast cancer. Presentations, papers and scientific discussions have expounded the mechanis...Bionovo Announces Third Quarter 2007 Financial Results
...dosing continues in the Phase 1 portion of the bzl101 Phase 1/2 clinical trial for advanced metastatic breast cancer. -- Bionovo presented data on bzl101 at the AACR-NCI-EORTC International Conference...r Targets and Cancer Therapeutics showing that bzl101 selectively elicits its cytotoxic activity on canc...Other TagsProbeProbeProbeProbeProbeInterestOther Contentsprojectsprojectsprojectsprojectsprojectsprojectsprojectsprojectscomplexitycomplexitycomplexitycomplexitycomplexitycomplexitycomplexitygenomicgenomicgenomicgenomicgenomicgenomicgenomicgenomicgenotypegenotypegenotypegenotypegenotypegenotypegenusgenusgenusgenusgenusdistributiondistributiondistributiondistributiondistributiondistributiondistributiondistributiondistributiongeographicgeographicgeographicgeographicgeographicgeographic
(Date:11/27/2009)...g unprecedented medical, economic burdens, study p...ews) -- The number of people with diabetes in the ...25 years, a new study predicts. , That would br... with the disease, up from 23.7 million today. , ...ith diabetes will triple, the study also warns, ri...
(Date:11/27/2009)... Specialist manufacturers who use medical load...illions of dollars by bringing in technology partn... numbers of pro-active medical manufacturers are c... stage of their projects, ensuring that progress w...s or potentially outdated technology. , ...
(Date:11/26/2009)...s, the number of Americans living with diabetes wi...2009 to 44.1 million in 2034. Over the same period...from $113 billion to $336 billion, even with no in...ased at the University of Chicago report in the De... those with diabetes covered by Medicare will rise...
(Date:11/26/2009)... No more letters from the North Pole, Textsant...essages from Santa , Nort...rational efficiencies at the North Pole Santa Clau...en all over the globe informed of his Christmas pr...;s research department have identified a large and...
(Date:11/26/2009)... Ennis & Ennis, P.A. is offering free nati... and Yasmin birth control pills who have suffered ...Stroke, Heart Attack or other related cardiac issu...l toll free at 1-800-856-6405 or go to the firm&rs...l out an online case evaluation form. , ...
Breaking Medicine News(10 mins):Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3[0] Diabetes Cases Expected to Double in 25 Years[0] Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells[0] Diabetes cases to double and costs to triple by 2034[1] Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes[0] Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills
(Date:11/24/2009)...us Research Institute (LRI) today named 12 new gra...million, recognize innovative work across a broad ...their creativity, novelty, and potential to drive ... and cure the complex disease of systemic lupus. ,...lupus researchers across the nation and include in...
(Date:11/24/2009)...sts have crystallised a protein that may help gut ...rotein could be used by probiotic producers to ide...t to people. , "Probiotics need to interact with ...and if they attach to surfaces in the gut they are...their activity," says Dr Nathalie Juge from the In...
(Date:11/24/2009)...mic-level action of a remarkable class of ring-sha...rs with the Lawrence Berkeley National Laboratory ...ystallography beamline at the Advanced Light Sourc...n gene expression and replication, and are vital t... infectious agents, such as the human papillomavir...
Breaking Biology News(10 mins):Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3A sticky solution for identifying effective probiotics 2Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4HerbalScience Research Demonstrates that Optimized Turmeric Extract Inhibits Amyloid Beta Accumulation a Hallmark of Alzheimers Disease 56123 1HerbalScience Research Demonstrates that Optimized Turmeric Extract Inhibits Amyloid Beta Accumulation a Hallmark of Alzheimers Disease 56123 2HerbalScience Research Demonstrates that Optimized Turmeric Extract Inhibits Amyloid Beta Accumulation a Hallmark of Alzheimers Disease 56123 3Oncothyreon to present at Rodman Renshaw Global Healthcare Conference 13822 1Echo Therapeutics to Present at Rodman 26 Renshaw 2009 Annual Global Investment Conference 56117 1Echo Therapeutics to Present at Rodman 26 Renshaw 2009 Annual Global Investment Conference 56117 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |